The early diagnosis of prostate cancer and subsequent access to the treatment options helps to achieve optimal cancer outcomes. As the treatment options for patients with advanced prostate cancer continues to evolve, patients need to access a multidisciplinary team (MDT) meeting to receive best-practice care.
In this paper a MEDLINE review was performed to assess clinical decision making in the context of MDT discussions for patients with advanced prostate cancer.
From 441 returned articles and abstracts, 50 articles were assessed for eligibility and 16 articles included for analysis. Sixteen articles were identified, 9 of the 16 articles used quantitative methodology including three retrospective analysis of clinical registry data, patient medical records and/or MDT meeting notes and three cross-sectional surveys. Other study designs included one observation study and one study using a combination of qualitative and quantitative methodologies and one mini-review. There were also four editorials included in the review and two consensus statements.
This paper highlights the important role the inter-disciplinary MDT has on shared decision making for men with advanced prostate cancer. The application of MDT care is a rapidly growing trend in uro-oncology and an efficient MDT service requires further research to assess its efficiency so that it may expand through all aspect of uro-oncology.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Murphy DG, Hofman MS, Azad A, Violet J, Hicks RJ, Lawrentschuk N (2019) Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. BJU Int. https://doi.org/10.1111/bju.14814
Mottet N, Bergh RCN Van Den, Vice-chair PC, Santis M De, Gillessen S, Govorov A, et al (2018) EAU-ESUR-ESTRO-SIOG Guidelines on Prostate Cancer/Guias Europeas. Eur Assoc Urol. ISBN 978-94-92671-05-9
Horwich A, Parker C, Bangma C, Kataja V (2010) Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. Suppl 5:v129–v133. https://doi.org/10.1093/annonc/mdq174
Hurwitz LM, Cullen J, Elsamanoudi S, Kim DJ, Hudak J, Colston M, et al (2016) A prospective cohort study of treatment decision-making for prostate cancer following participation in a multidisciplinary clinic. Urol Oncol 34(5):233.e17–233.e25. https://doi.org/10.1016/j.urolonc.2015.11.014
Borras JM, Albreht T, Audisio R, Briers E, Casali P, Esperou H et al (2014) Policy statement on multidisciplinary cancer care. Eur J Cancer 50(3):475–480. https://doi.org/10.1016/j.ejca.2013.11.01
Huay C (2020) Surgical perspectives of locally advanced prostate cancer. World J Urol (In Press)
Sathianathen NJ, Koschel S, Thangasamy IA, Teh J, Alghazo O, Butcher G et al (2019) Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur Urol 77(3):365–372. https://doi.org/10.1016/j.eururo.2019.09.004
Hess-Busch Y, Hadaschik B, Hess J (2019) M0CRPC overview of management options. World J Urol. https://doi.org/10.1007/s00345-019-02997-z
Azad A (2020) Metastatic hormone sensitive Pca: selection of systemic treatment options. World J Urol (In Press)
Walz J (2020) Metastatic hormone sensitive Pca: local treatment strategies. World J Urol (In Press)
Montorsi F (2020) On being sick and tired. Eur Urol Oncol 3(1):7–9. https://doi.org/10.1016/j.euo.2019.08.016
Bravi CA, Tin A, Vertosick E, Mazzone E, Bandini M, Dell’Oglio P et al (2020) Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy. Urol Oncol 38(4):204–209. https://doi.org/10.1016/j.urolonc.2019.09.018
Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Fossati N et al (2019) Contemporary Trends and survival outcomes after aborted radical prostatectomy in lymph node metastatic prostate cancer patients. Eur Urol Focus 5(3):381–388. https://doi.org/10.1016/j.euf.2018.01.009
Lowrance WT, Murad MH, Oh WK, Jarrard DF, Resnick MJ, Cookson MS (2018) Castration-resistant prostate cancer: AUA guideline amendment 2018. J Urol 200(6):1264–1272. https://doi.org/10.1016/j.juro.2018.07.090
Arksey H, O’Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol Theory Pract 8(1):19–32. https://doi.org/10.1080/1364557032000119616
Colquhoun HL, Levac D, O’Brien KK, Straus S, Tricco AC, Perrier L et al (2014) Scoping reviews: time for clarity in definition, methods, and reporting. J Clin Epidemiol 67(12):1291–1294. https://doi.org/10.1016/j.jclinepi.2014.03.013
Rourke K (2018) Getting to know each other: Integrating radiation and medical oncology training in urology (and urology training in oncology). Can Urol Assoc J 12(10):326–327. https://doi.org/10.5489/cuaj.5607
Heidenreich A (2019) Multidisciplinary team meetings for prostate cancer treatment: we can do much better in daily life. Oncol Res Treatm 42(7–8):363–365. https://doi.org/10.1159/000500426
Hoge C, Sidana A (2020) Multidisciplinary clinics: a possible means to help to eliminate racial disparities in prostate cancer. Cancer 126(12):2938–2939. https://doi.org/10.1002/cncr.32841
Onukwugha E, Mullins CD, Doren Hsu V, Seal B, Hussain A (2011) Effect of urologists and medical oncologists on treatment of elderly men with stage IV prostate cancer. Urology 77(5):1088–1095. https://doi.org/10.1016/j.urology.2010.11.059
Zereshkian A, Cao X, Puts M, Dawdy K, Di Prospero L, Alibhai S et al (2019) Do Canadian radiation oncologists consider geriatric assessment in the decision-making process for treatment of patients 80 years and older with non-metastatic prostate cancer?—national survey. J Geriatr Oncol 10(4):659–665. https://doi.org/10.1016/j.jgo.2019.01.015
Poon DMC, Ma WK, Chan TW, Ho FKL, Ho LY, Leung AKC et al (2019) Management of advanced prostate cancer in Hong Kong: insights from an APCCC-derived survey. Asia Pac J Clin Oncol Suppl 6:8–13. https://doi.org/10.1111/ajco.13247
Saad F, Canil C, Finelli A, Hotte SJ, Malone S, Shayegan B et al (2019) A A Canadian consensus forum on the management of patients with advanced prostate cancer. Can Urol Assoc J 14(4):E137–E149. https://doi.org/10.5489/cuaj.6082
Brown B, Young J, Smith DP, Kneebone AB, Brooks AJ, Egger S et al (2018) A multidisciplinary team-oriented intervention to increase guideline recommended care for high-risk prostate cancer: a stepped-wedge cluster randomised implementation trial. Implement Sci 13(1):43. https://doi.org/10.1186/s13012-018-0733-x
Betschart P, Babst C, Schmid S, Rothermundt C, Abt D, Schwab C et al (2019) Shared decision-making for patients with advanced urological malignancies: evaluation of a joint urological-oncological clinic model. Oncol Res Treat 42(7–8):366–374. https://doi.org/10.1159/000499721
Knipper S, Sadat-Khonsari M, Boehm K, Mandel P, Budäus L, Steuber T et al (2019) Impact of adherence to multidisciplinary recommendations for adjuvant treatment in radical prostatectomy patients with high risk of recurrence. Clin Genitourin Cancer 18(2):e112–e121. https://doi.org/10.1016/j.clgc.2019.09.007
Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S et al (2020) Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer 126(3):506–514. https://doi.org/10.1002/cncr.32570
De Luca S, Fiori C, Tucci M, Poggio M, Allis S, Bollito E, Solitro F, Passera R, Buttigliero CPF (2019) Prostate cancer management at an Italian tertiary referral centre: does multidisciplinary team meeting influence diagnostic and therapeutic decision-making process? A snapshot of the everyday clinical practice. Minerva Urol Nefrol 71(6):576–582. https://doi.org/10.23736/S0393-2249.19.03231-4
Herlemann A, Washington SL, Cooperberg MR (2019) Health care delivery for metastatic hormone-sensitive prostate cancer across the globe. Eur Urol Focus 5(2):155–158. https://doi.org/10.1016/j.euf.2018.12.003
Brausi M, Hoskin P, Andritsch E, Banks I, Beishon M, Boyle H et al (2020) ECCO essential requirements for quality cancer care: prostate cancer. Crit Rev Oncol Hematol 148:102861. https://doi.org/10.1016/j.critrevonc.2019.102861
Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A et al (2020) Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019[formula presented]. Eur Urol 77(4):508–547. https://doi.org/10.1016/j.eururo.2020.01.012
Thangasamy IA, Kwan EM, Teh J, Sathianathen N, Alghazo O, Siva S et al (2019) Novel agents for metastatic hormone-sensitive prostate cancer—a practice guide for urologists. BJU Int 125(3):342–345. https://doi.org/10.1111/bju.14936
Rao K, Manya K, Azad A, Lawrentschuk N, Bolton D, Davis ID et al (2014) Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre—impact on clinical decision-making and implications for patient inclusion. BJU Int 114(Suppl 1):50–4. https://doi.org/10.1111/bju.12764
Butcher HSP (2018) Patient engagement and empowerment driving patient centred care. In: In Velikova G, Fallowfield L, Younger J et al (eds) Problem solving in patient centred and integrated cancer care. EBN Health, Witney, pp 24–30
Bultijnck R, Deforche B, Borrey N et al (2020) Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial. World J Urol. https://doi.org/10.1007/s00345-020-03098-y
Han S, Woo S, Kim YJ, Suh CH (2018) Impact of 68 Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 74(2):179–190. https://doi.org/10.1016/j.eururo.2018.03.030
Van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B et al (2016) 68 Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int 117(5):732–739. https://doi.org/10.1111/bju.13397
Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I et al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77(4):403–417. https://doi.org/10.1016/j.eururo.2019.01.049
De Bruycker A, Tran PT, Achtman AH et al (2020) Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries. World J Urol. https://doi.org/10.1007/s00345-019-03063-4
Sundi D, Cohen JE, Cole AP, Neuman BP, Cooper J, Faisal FA et al (2015) Establishment of a new prostate cancer multidisciplinary clinic: format and initial experience. Prostate 75(2):191–199. https://doi.org/10.1002/pros.22904
Kinnear N, Smith R, Hennessey DB, Bolton D, Sengupta S (2017) Implementation rates of uro-oncology multidisciplinary meeting decisions. BJU Int 120(Suppl 3):15–20. https://doi.org/10.1111/bju.13892
Prades J, Remue E, van Hoof E, Borras JM (2015) Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy 119(4):464–474. https://doi.org/10.1016/j.healthpol.2014.09.006
Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P et al (2016) The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treatm Rev 42:56–72. https://doi.org/10.1016/j.ctrv.2015.11.007
Selby P, Liu L, Downing A, Banks I, Wilson RRS, Meunier F, Rochon J, Morris E, Seymour M, Gregory WML, Boaz A (2019) How can clinical research improve European health outcomes in cancer? J cancer Surg 20:100182
Shore ND (2013) Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist. Prostate Cancer and Prostatic Dis 16(1):1–6. https://doi.org/10.1038/pcan.2012.23
Conflict of interest
None to declare.
Research involving Human Participants and/or Animals
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Holmes, A., Kelly, B.D., Perera, M. et al. A systematic scoping review of multidisciplinary cancer team and decision-making in the management of men with advanced prostate cancer. World J Urol (2020). https://doi.org/10.1007/s00345-020-03265-1
- Prostate neoplasm
- Interdisciplinary communication
- Disease management
- Clinical oncology